Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes

18. dubna 2017 aktualizováno: AstraZeneca

A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase III Trial to Evaluate the Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise

The purpose of this clinical research study is to learn if BMS-512148 (Dapagliflozin) can help reduce the blood sugar levels in subjects with Type 2 Diabetes who are not well controlled on diet and exercise alone. The safety of this treatment will also be studied

Přehled studie

Postavení

Dokončeno

Podmínky

Intervence / Léčba

Typ studie

Intervenční

Zápis (Aktuální)

497

Fáze

  • Fáze 3

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

  • Indie
      • Ahmedabad, Indie, 380 015
        • Local Institution
      • Bangalore, Indie, 560 043
        • Local Institution
      • Bangalore, Indie, 560 052
        • Local Institution
      • Jaipur, Indie, 302001
        • Local Institution
      • Jaipur, Indie, 302016
        • Local Institution
  • Jižní Afrika
    • Gauteng
      • Benoni, Gauteng, Jižní Afrika, 1501
        • Local Institution
      • Soweto, Gauteng, Jižní Afrika, 1818
        • Local Institution
    • Western Cape
      • Paarl, Western Cape, Jižní Afrika, 7646
        • Local Institution
      • Tygerberg, Western Cape, Jižní Afrika, 7505
        • Local Institution
  • Kanada
    • Alberta
      • Calgary, Alberta, Kanada, T3C 3P1
        • Local Institution
    • British Columbia
      • Coquitlam, British Columbia, Kanada, V3K 3V9
        • Local Institution
    • Manitoba
      • Winnipeg, Manitoba, Kanada, R3E 3P4
        • Local Institution
    • New Brunswick
      • Bathurst, New Brunswick, Kanada, E2A 4X7
        • Local Institution
    • Ontario
      • Ajax, Ontario, Kanada, L1S 7J5
        • Local Institution
      • Toronto, Ontario, Kanada, M9W 4L6
        • Local Institution
      • Waterloo, Ontario, Kanada, N2T 2Z6
        • Local Institution
    • Quebec
      • Drummondville, Quebec, Kanada, J2B 7T1
        • Local Institution
      • L'Ancienne Lorette, Quebec, Kanada, G2E 2X1
        • Local Institution
      • St-Leonard, Quebec, Kanada, H1S 3A9
        • Local Institution
  • Mexiko
      • Durango, Mexiko, 34000
        • Local Institution
      • Mexico City, Mexiko, 06700
        • Local Institution
      • Veracruz, Mexiko, 91910
        • Local Institution
    • Distrito Federal
      • Df, Distrito Federal, Mexiko, 11800
        • Local Institution
    • Jalisco
      • Guadalajara, Jalisco, Mexiko, 44670
        • Local Institution
    • Nuevo Leon
      • Monterrey, Nuevo Leon, Mexiko, 64060
        • Local Institution
    • Yucatan
      • Merida, Yucatan, Mexiko, 97070
        • Local Institution
  • Portoriko
      • Ponce, Portoriko, 00716
        • Local Institution
      • Ponce, Portoriko, 00717
        • Local Institution
  • Ruská Federace
      • Kursk, Ruská Federace, 305035
        • Local Institution
      • Saint-Petersburg, Ruská Federace, 191015
        • Local Institution
      • Saratov, Ruská Federace, 410012
        • Local Institution
      • Smolensk, Ruská Federace, 214018
        • Local Institution
      • St. Petersburg, Ruská Federace, 195112
        • Local Institution
      • St. Petersburg, Ruská Federace, 195257
        • Local Institution
      • St. Petersburg, Ruská Federace, 197341
        • Local Institution
      • St.Petersburg, Ruská Federace, 197022
        • Local Institution
  • Spojené státy
    • Arizona
      • Litchfield Park, Arizona, Spojené státy, 85340
        • Dedicated Clinical Research
      • Phoenix, Arizona, Spojené státy, 85051
        • 43rd Medical Associates, P.C.
      • Tempe, Arizona, Spojené státy, 85282
        • Clinical Research Advantage, Inc.
    • California
      • Fresno, California, Spojené státy, 93720
        • Valley Research
      • Lomita, California, Spojené státy, 90717
        • Marina Raikhel, Md, Faafp
      • Los Gatos, California, Spojené státy, 95032
        • Richard S. Cherlin, MD
      • Tustin, California, Spojené státy, 92780
        • Orange County Research Center
    • Colorado
      • Greeley, Colorado, Spojené státy, 80634
        • Family Physicians Of Greeley
    • Connecticut
      • New London, Connecticut, Spojené státy, 06320
        • Coastal Connecticut Research, LLC
    • Florida
      • Altamonte Springs, Florida, Spojené státy, 32701
        • Central Florida Clinical Trials, Inc.
      • Jacksonville, Florida, Spojené státy, 32205
        • Westside Center for Clinical Research
      • Marianna, Florida, Spojené státy, 32446
        • Panhandle Family Care Associates
    • Georgia
      • Roswell, Georgia, Spojené státy, 30076
        • Endocrine Research Solutions, Inc.
    • Mississippi
      • Belzoni, Mississippi, Spojené státy, 39038
        • Belzoni Clinical Research
    • New Jersey
      • Hamilton, New Jersey, Spojené státy, 08690
        • R-Research
    • New York
      • Syracuse, New York, Spojené státy, 13210
        • Internist Associates Of Central New York
      • West Seneca, New York, Spojené státy, 14224
        • Southgate Medical Group
    • North Carolina
      • Morehead City, North Carolina, Spojené státy, 28557
        • Down East Medical Associates, PA
    • Ohio
      • Akron, Ohio, Spojené státy, 44319
        • James J. Brown, Md
    • Oklahoma
      • Oklahoma, Oklahoma, Spojené státy, 73170
        • Integris Family Care South
    • South Carolina
      • Taylors, South Carolina, Spojené státy, 29687
        • Southeastern Research Associates, Inc.
    • Texas
      • San Antonio, Texas, Spojené státy, 78224
        • Abbott Clinical Research Group, Inc
    • Utah
      • Midvale, Utah, Spojené státy, 84047
        • Avastra Clinical Trials
      • Salt Lake City, Utah, Spojené státy, 84102
        • Optimum Clinical Research, Inc.
    • Washington
      • Olympia, Washington, Spojené státy, 98502
        • Capital Clinical Research Center
      • Spokane, Washington, Spojené státy, 99216
        • Stephen G. Danley, Do

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let až 77 let (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • Male and females, ≥18 to ≤77 years old, with type 2 diabetes mellitus
  • Subjects must have central laboratory pre-randomization A1C ≥7.0 and ≤ 10.0%
  • C-peptide ≥ 1.0 ng/mL (0.34 nmol/L)
  • Body Mass Index ≤ 45 kg/m²
  • Must be able to perform self monitoring of blood glucose

Exclusion Criteria:

  • aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >3* upper limit of normal (ULN)
  • Serum Total bilirubin >2 mg/dL (34.2 µmol/L)
  • Creatinine kinase >3* ULN
  • Serum creatinine ≥1.50 mg/dL (133 µmol/L) for male subjects, ≥1.40 mg/dL (124 µmol/L) for female subjects
  • Currently unstable or serious cardiovascular, renal, hepatic, hematological, oncological, endocrine, psychiatric, or rheumatic diseases

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Dvojnásobek

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Dapagliflozin 1 mg
Dapagliflozin: 1 mg
Lék: Dapagliflozin
Tablets, Oral, Once Daily, Up to 24 weeks
Ostatní jména:
  • BMS-512148
  • Farxiga™
Experimentální: Dapagliflozin 2.5 mg
Dapagliflozin: 2.5 mg
Lék: Dapagliflozin
Tablets, Oral, Once Daily, Up to 24 weeks
Ostatní jména:
  • BMS-512148
  • Farxiga™
Experimentální: Dapagliflozin 5 mg
Dapagliflozin: 5 mg
Lék: Dapagliflozin
Tablets, Oral, Once Daily, Up to 24 weeks
Ostatní jména:
  • BMS-512148
  • Farxiga™
Komparátor placeba: Placebo
Placebo: 0 mg
Lék: Placebo
Tablets, Oral, Once Daily, Up to 24 weeks

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 Last Observation Carried Forward (LOCF) - All Randomized Participants
Časové okno: Baseline (Day 1), Week 24
Adjusted mean change in HbA1c from baseline at Week 24, or the last post-baseline measurement prior to Week 24 if no Week 24 assessment was available was determined(LOCF). HbA1c was measured as percent of hemoglobin by a central laboratory. Data after rescue medication (metformin) was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. HbA1c values were obtained at enrollment, lead-in, and at Day 1, Weeks 4, 8, 12, 16, 20, and 24 in the double-blind period.
Baseline (Day 1), Week 24

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Adjusted Mean Change From Baseline in Total Body Weight at Week 24 (LOCF) - Randomized Participants
Časové okno: Baseline (Day 1), Week 24
Adjusted mean change in total body weight from baseline at Week 24, or the last post-baseline measurement prior to Week 24 if no Week 24 assessment was available LOCF was determined. Data after rescue medication (metformin) was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. Body weight was measured in kilograms (kg) at qualification, lead-in, Day 1, Weeks 1, 2, 4, 8, 12, 16, 20, and 24 during double-blind period.
Baseline (Day 1), Week 24
Adjusted Mean Change From Baseline in Fasting Plasma Glucose at Week 24 (LOCF) - Randomized Participants
Časové okno: Baseline (Day 1), Week 24
Adjusted mean change in fasting plasma glucose (FPG) from baseline at Week 24 (LOCF) was determined. Data after rescue medication (metformin) was excluded from this analysis. FPG was measured as milligrams per deciliter (mg/dL) by a central laboratory at qualification, lead-in, Day 1, Weeks 1, 2, 4, 8, 12, 16, 20, and 24 during double-blind period. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication.
Baseline (Day 1), Week 24
Adjusted Mean Change From Baseline in Effect on 2-hour Post Liquid Meal Glucose at Week 24 (LOCF) - Randomized Participants
Časové okno: Baseline (Day 1), Week 24
Liquid meal tolerance tests (MTTs) were scheduled to occur at Day 1 visit (MTT was to be completed 2 hours prior to first dose of treatment) and at Week 24 / End of treatment visit, or Rescue visit for participants meeting criteria for rescue due to lack of glycemic control. At Week 24, study treatment was given 1 hour before MTT was administered. Participant fasted for at least 10 hours (h) prior to both visits and abstained from tobacco, alcohol, and caffeine for 24 h prior to the MTT. The liquid meal supplement was administered over 10 minutes, starting immediately after Time 0 blood sample was drawn. Blood samples for post-liquid meal Glucose were obtained at 30, 60, 120, and 180 minutes after ingesting the liquid supplement. Glucose was measured in milligrams per deciliter (mg/dL) by a central laboratory. Baseline was defined as the last assessment prior to the start date and time of the first dose of double-blind study medication.
Baseline (Day 1), Week 24
Adjusted Percentage of Participants Achieving a Therapeutic Glycemic Response at Week 24 (LOCF) - Randomized Participants
Časové okno: Baseline (Day 1), Week 24
Therapeutic glycemic response was defined as HbA1c less than 7.0%. n=Number of participants with HBA1c less than (<) 7 % at Week 24, last observation carried forward (LOCF) while N=number of randomized participants with non-missing baseline and Week 24 (LOCF) values. Percent=n/N and was adjusted for Baseline HbA1c. Data after rescue medication (metformin) was excluded from this analysis. HbA1c was measured as a percent of hemoglobin.
Baseline (Day 1), Week 24
Adjusted Mean Change From Baseline in Waist Circumference at Week 24 (LOCF) - Randomization Participants
Časové okno: Baseline (Day 1), Week 24
Adjusted mean waist circumference values from baseline to Week 24 (or the last post-baseline measurement prior to Week 24 if no Week 24 assessment was available, last observation carried forward, (LOCF) was determined. Data after rescue medication (metformin) was excluded from this analysis. Waist circumference was measured centimeters (cm) and obtained at lead-in, Day 1, and Week 24 of the double-blind period. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication.
Baseline (Day 1), Week 24
Number of Participants With Deaths, Serious AEs (SAEs), Adverse Events (AEs), Discontinuation Due to AEs, During the 12 Week Double Blind Period, Including Data After Rescue - All Treated Participants
Časové okno: Day 1 of Double Blind Period to end of Week 24 Plus 30 days
Medical Dictionary for Regulatory Activities (MedDRA), version 12.1 AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug as per the investigator. Baseline to last dose plus 4 days for AEs, plus 30 days for SAEs. Data after rescue included.
Day 1 of Double Blind Period to end of Week 24 Plus 30 days
Number of Participants With Adverse Events of Special Interest During the 12 Week Double Blind Period - All Treated Participants
Časové okno: Baseline to last dose plus 4 days in 12 Week Double Blind Period
Participants with AEs of hypoglycemia, cardiac/vascular disorders, renal impairment or failure, volume depletion (hypotension/dehydration/hypovolemia), fractures, urinary stones, and other reports suggestive of genital infection or urinary tract infection (UTI) were summarized using MedDRA version 12.1. Data after rescue included for all AEs of special interest except hypoglycemia; hypoglycemia AEs were prior to rescue. Major hypoglycemic episode: symptomatic requiring 3rd party assistance due to severe impairment in consciousness or behavior with a glucose value < 54 mg/dL and prompt recovery after glucose/glucagon; Minor: either symptomatic with glucose measurement < 63 mg/dL, regardless of need for 3rd party assistance, or asymptomatic with glucose < 63 mg/dL that does not qualify as major; Other: suggestive but not meeting criteria for major or minor.
Baseline to last dose plus 4 days in 12 Week Double Blind Period
Mean Change From Baseline in Seated Systolic and Diastolic Blood Pressure at Week 24, Including Data After Rescue - Treated Participants
Časové okno: Baseline (Day 1), Week 24
Blood pressure values were obtained on Day 1, Weeks 1, 2, 4, 8, 12, 16, 20, and 24 in the double blind period, after the participant was seated for quietly for 5 minutes; the same arm (right or left) was used consistently through out the study. Measurements were taken at least 10 hours after the last ingestion of caffeine, alcohol, or nicotine. Blood pressure was measured in millimeters of mercury (mmHg). Data after rescue were also included. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication.
Baseline (Day 1), Week 24
Mean Change From Baseline in Seated Heart Rate at Week 24 - Treated Participants
Časové okno: Baseline (Day 1), Week 24
Heart rate values were obtained after the participant was seated for quietly for 5 minutes; the same arm (right or left) was used consistently through out the study. Measurements were taken at least 10 hours after the last ingestion of caffeine, alcohol, or nicotine. Heart rate was measured in beats per minute (bpm). Data after rescue were also included. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication.
Baseline (Day 1), Week 24
Number of Participants With Normal or Abnormal Electrocardiogram Summary Tracing at Week 24 (LOCF) - Treated Participants
Časové okno: Week 24
12-Lead electrocardiograms (ECGs) were performed at Day -14 and Week 24/End of treatment visit (last observation carried forward) on participants who were supine. ECGs were assessed by the investigator. Baseline (BL) was Day -14 for this parameter.
Week 24
Number of Participants With Marked Laboratory Abnormalities in 24 Week Double Blind Treatment Period - Treated Participants
Časové okno: Baseline to Week 24/end of treatment plus 4 days
Safety laboratory measurements were obtained at Day 1, Weeks 1, 2, 4, 8, 12, 20, and 24 in the double blind Period. Baseline was defined as the last assessment prior to the start of the first dose of the double-blind study medication. Data included from baseline up to and including the last day of treatment plus 4 days. Data after rescue was also included. Abbreviations; Pretreatment (PreRX); grams per deciliter (g/dL); upper limit of normal (ULN); milliequivalent per liter (mEq/L); greater than (>) less than (<); Units per liter (U/L), alanine aminotransferase (ALT); aspartate aminotransferase (AST); alkaline phosphatase (ALP); blood urea nitrogen (BUN). Marked abnormality Low (High) defined: hemoglobin <6 (>18 females or >20 males) g/dL; hematocrit <20% ( >55% females or >60% males); BUN (>60 mg/dL) or Urea >21.4 mmol/L; creatinine (>=1.5*preRX, >=2.5 mg/dL); AST and ALT >3*ULN; bilirubin >1.5*ULN; ALP >1.5*ULN.
Baseline to Week 24/end of treatment plus 4 days

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

AstraZeneca

Spolupracovníci

Bristol-Myers Squibb

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Obecné publikace

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

22. září 2008

Primární dokončení (Aktuální)

29. prosince 2009

Dokončení studie (Aktuální)

29. prosince 2009

Termíny zápisu do studia

První předloženo

15. srpna 2008

První předloženo, které splnilo kritéria kontroly kvality

15. srpna 2008

První zveřejněno (Odhad)

18. srpna 2008

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

20. dubna 2017

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

18. dubna 2017

Naposledy ověřeno

1. dubna 2017

Více informací

Termíny související s touto studií

Klíčová slova

Další relevantní podmínky MeSH

Další identifikační čísla studie

  • MB102-032

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

produkt vyrobený a vyvážený z USA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Klinické studie na Diabetes mellitus 2. typu

Prohledejte podobné pokusy

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

CROs by country

CROs in Uruguay

Podmínky

Vzácné nemoci

Drogové intervence

Doplňky stravy

Sponzor / Spolupracovníci

Místa

3
Předplatit